• Compass Pathways' COMP360 psilocybin therapy demonstrated rapid and durable efficacy in new six-month data from a second Phase 3 trial for treatment-resistant depression, announced on July 7, 2026.
  • This positive data further strengthens the company's New Drug Application (NDA) submission, which is under rolling review by the FDA and has a Commissioner’s National Priority Voucher (announced April 2026).
  • Analysts have since reiterated positive ratings and increased price targets, anticipating a potential launch in H1 2027.